Open Access
Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
Тип публикации: Journal Article
Дата публикации: 2013-10-08
БС1
SJR: 2.28
CiteScore: 15.6
Impact factor: 8.6
ISSN: 16197070, 16197089
PubMed ID:
24100768
General Medicine
Radiology, Nuclear Medicine and imaging
Краткое описание
The radiolanthanide 161Tb (T 1/2 = 6.90 days, Eβ− av = 154 keV) was recently proposed as a potential alternative to 177Lu (T 1/2 = 6.71 days, Eβ− av = 134 keV) due to similar physical decay characteristics but additional conversion and Auger electrons that may enhance the therapeutic efficacy. The goal of this study was to compare 161Tb and 177Lu in vitro and in vivo using a tumour-targeted DOTA-folate conjugate (cm09). 161Tb-cm09 and 177Lu-cm09 were tested in vitro on folate receptor (FR)-positive KB and IGROV-1 cancer cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay. In vivo 161Tb-cm09 and 177Lu-cm09 (10 MBq, 0.5 nmol) were investigated in two different tumour mouse models with regard to the biodistribution, the possibility for single photon emission computed tomography (SPECT) imaging and the antitumour efficacy. Potentially undesired side effects were monitored over 6 months by determination of plasma parameters and examination of kidney function with quantitative SPECT using 99mTc-dimercaptosuccinic acid (DMSA). To obtain half-maximal inhibition of tumour cell viability a 4.5-fold (KB) and 1.7-fold (IGROV-1) lower radioactivity concentration was required for 161Tb-cm09 (IC50 ~0.014 MBq/ml and ~2.53 MBq/ml) compared to 177Lu-cm09 (IC50 ~0.063 MBq/ml and ~4.52 MBq/ml). SPECT imaging visualized tumours of mice with both radioconjugates. However, in therapy studies 161Tb-cm09 reduced tumour growth more efficiently than 177Lu-cm09. These findings were in line with the higher absorbed tumour dose for 161Tb-cm09 (3.3 Gy/MBq) compared to 177Lu-cm09 (2.4 Gy/MBq). None of the monitored parameters indicated signs of impaired kidney function over the whole time period of investigation after injection of the radiofolates. Compared to 177Lu-cm09 we demonstrated equal imaging features for 161Tb-cm09 but an increased therapeutic efficacy for 161Tb-cm09 in both tumour cell lines in vitro and in vivo. Further preclinical studies using other tumour-targeting radioconjugates are clearly necessary to draw final conclusions about the future clinical perspectives of 161Tb.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.
Топ-30
Журналы
|
2
4
6
8
10
12
14
|
|
|
Journal of Nuclear Medicine
13 публикаций, 9.29%
|
|
|
Applied Radiation and Isotopes
9 публикаций, 6.43%
|
|
|
EJNMMI Physics
8 публикаций, 5.71%
|
|
|
European Journal of Nuclear Medicine and Molecular Imaging
6 публикаций, 4.29%
|
|
|
EJNMMI Radiopharmacy and Chemistry
6 публикаций, 4.29%
|
|
|
EJNMMI Research
6 публикаций, 4.29%
|
|
|
Pharmaceuticals
4 публикации, 2.86%
|
|
|
Frontiers in Medicine
4 публикации, 2.86%
|
|
|
Coordination Chemistry Reviews
4 публикации, 2.86%
|
|
|
Nuclear Medicine and Biology
4 публикации, 2.86%
|
|
|
Pharmaceutics
3 публикации, 2.14%
|
|
|
Journal of Radioanalytical and Nuclear Chemistry
3 публикации, 2.14%
|
|
|
Physics in Medicine and Biology
3 публикации, 2.14%
|
|
|
Molecular Pharmaceutics
3 публикации, 2.14%
|
|
|
Molecules
2 публикации, 1.43%
|
|
|
Scientific Reports
2 публикации, 1.43%
|
|
|
Journal of Labelled Compounds and Radiopharmaceuticals
2 публикации, 1.43%
|
|
|
Inorganic Chemistry
2 публикации, 1.43%
|
|
|
Dalton Transactions
2 публикации, 1.43%
|
|
|
International Journal of Radiation Biology
2 публикации, 1.43%
|
|
|
Research Square
2 публикации, 1.43%
|
|
|
Journal of Medicinal Chemistry
2 публикации, 1.43%
|
|
|
Russian Chemical Reviews
1 публикация, 0.71%
|
|
|
Recent Results in Cancer Research
1 публикация, 0.71%
|
|
|
British Journal of Radiology
1 публикация, 0.71%
|
|
|
EPJ Web of Conferences
1 публикация, 0.71%
|
|
|
Cancers
1 публикация, 0.71%
|
|
|
Brazilian Journal of Physics
1 публикация, 0.71%
|
|
|
Annals of Nuclear Medicine
1 публикация, 0.71%
|
|
|
2
4
6
8
10
12
14
|
Издатели
|
5
10
15
20
25
30
35
40
45
|
|
|
Springer Nature
43 публикации, 30.71%
|
|
|
Elsevier
27 публикаций, 19.29%
|
|
|
Society of Nuclear Medicine
13 публикаций, 9.29%
|
|
|
MDPI
12 публикаций, 8.57%
|
|
|
American Chemical Society (ACS)
9 публикаций, 6.43%
|
|
|
Wiley
6 публикаций, 4.29%
|
|
|
Frontiers Media S.A.
5 публикаций, 3.57%
|
|
|
Royal Society of Chemistry (RSC)
5 публикаций, 3.57%
|
|
|
IOP Publishing
4 публикации, 2.86%
|
|
|
Taylor & Francis
3 публикации, 2.14%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 публикации, 2.14%
|
|
|
SAGE
2 публикации, 1.43%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 0.71%
|
|
|
British Institute of Radiology
1 публикация, 0.71%
|
|
|
EDP Sciences
1 публикация, 0.71%
|
|
|
Pleiades Publishing
1 публикация, 0.71%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 публикация, 0.71%
|
|
|
De Gruyter Brill
1 публикация, 0.71%
|
|
|
Edizioni Minerva Medica
1 публикация, 0.71%
|
|
|
Allerton Press
1 публикация, 0.71%
|
|
|
5
10
15
20
25
30
35
40
45
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Войти с ORCID
Метрики
140
Всего цитирований:
140
Цитирований c 2025:
49
(35%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Müller C. et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate // European Journal of Nuclear Medicine and Molecular Imaging. 2013. Vol. 41. No. 3. pp. 476-485.
ГОСТ со всеми авторами (до 50)
Скопировать
Müller C., Reber J., Haller S., Dorrer H., Bernhardt P., Zhernosekov K., Türler A., Schibli R. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate // European Journal of Nuclear Medicine and Molecular Imaging. 2013. Vol. 41. No. 3. pp. 476-485.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1007/s00259-013-2563-z
UR - https://doi.org/10.1007/s00259-013-2563-z
TI - Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
T2 - European Journal of Nuclear Medicine and Molecular Imaging
AU - Müller, Cristina
AU - Reber, Josefine
AU - Haller, Stephanie
AU - Dorrer, Holger
AU - Bernhardt, Peter
AU - Zhernosekov, Konstantin
AU - Türler, Andreas
AU - Schibli, Roger
PY - 2013
DA - 2013/10/08
PB - Springer Nature
SP - 476-485
IS - 3
VL - 41
PMID - 24100768
SN - 1619-7070
SN - 1619-7089
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2013_Müller,
author = {Cristina Müller and Josefine Reber and Stephanie Haller and Holger Dorrer and Peter Bernhardt and Konstantin Zhernosekov and Andreas Türler and Roger Schibli},
title = {Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2013},
volume = {41},
publisher = {Springer Nature},
month = {oct},
url = {https://doi.org/10.1007/s00259-013-2563-z},
number = {3},
pages = {476--485},
doi = {10.1007/s00259-013-2563-z}
}
Цитировать
MLA
Скопировать
Müller, Cristina, et al. “Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 3, Oct. 2013, pp. 476-485. https://doi.org/10.1007/s00259-013-2563-z.
Ошибка в публикации?